TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Bio Vitos Pharma AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Turnover |
72
|
2,012
|
882 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-13,034
|
-8,642
|
-9,957 |
| EBITDA |
-2,155
|
-2,354
|
-5,196 |
| Total assets |
10,597
|
22,783
|
17,675 |
| Current assets |
246
|
3,434
|
3,490 |
| Current liabilities |
257
|
677
|
1,020 |
| Equity capital |
10,340
|
22,105
|
16,654 |
| - share capital |
3,723
|
2,873
|
2,067 |
| Employees (average) |
1
|
1
|
5 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Solvency |
97.6%
|
97.0%
|
94.2% |
| Turnover per employee |
72
|
2,012
|
176 |
| Profit as a percentage of turnover |
-18102.8%
|
-429.5%
|
-1128.9% |
| Return on assets (ROA) |
-123.0%
|
-37.9%
|
-56.3% |
| Current ratio |
95.7%
|
507.2%
|
342.2% |
| Return on equity (ROE) |
-126.1%
|
-39.1%
|
-59.8% |
| Change turnover | |||
| Change turnover % | 18% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % | -17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.